Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
When thinking about multiple myeloma chemotherapy and heart damage it important to understand that the key is the condition of your heart before undergoing those chemotherapy regimens known to cause heart damage. As the saying goes, an ounce of prevention is worth a pound of cure.
To say that over 18 percent of patients undergoing carfilzomib experienced heart damage overlooks what I have come to believe is the central issue. The risk of damage to the healthy heart is less than the risk of heart damage to a weak heart.
While this may sound obvious to you the next step is to figure our how to strengthen the heart of a cancer patient about to undergo, undergoing or has already undergone carfilzomib.
all can contribute to the heart’s well-being before, during and after chemotherapy.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
I am a long-term myeloma survivor who underwent a chemotherapy regimen known for possible heart damage. I underwent adiamycin (doxorubacin) as one of my induction therapies in early 1995. I developed chronic atrial fibrillation in the fall of 2010. I now exercise moderately but regularly, supplement with heart-healthy supplements and consume a heart healthy diet.
Here is my Multiple Myeloma story. I’ve learned a lot about managing multiple myeloma since my diagnosis in 1994. Though chemotherapy may be a necessary evil for the MM patient, it is important to understand that you can take evidence-based action against the collateral damage caused by chemotherapy.
If you have any questions scroll down the page, post a question or comment and I will reply to you ASAP.
“The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients…
Researchers gathered data from 24 studies reported from 2007 through 2017, which included information on 2,594 MM patients. They found 18.1 percent of patients who took carfilzomib experienced CVAE, with 8.2 percent of those cases being grade three or higher, meaning they are categorized as severe. For comparison, a similar review of bortezomib, another proteasome inhibitor, found just 3.8 percent of patients experienced CVAE and only 2.3 percent were severe…
Researchers say these findings are particularly important since there are already overlapping risk factors for both MM and cardiovascular diseases, such as older age and obesity. Previous studies have shown nearly two-thirds of MM patients had cardiovascular disease at baseline, and 70 percent experienced cardiovascular events within six years…
“Importance Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple myeloma can be potentially life-threatening and remain incompletely characterized. We performed the first systematic review and meta-analysis of carfilzomib-associated CVAE.
Main Outcomes and Measures Cardiovascular adverse events were defined as heart failure, hypertension, ischemia, and arrhythmia. All-grade and grades 3 or higher AEs and study characteristics were recorded.
Results A total of 514 studies were assessed for eligibility. Of those, 24 studies were eligible, including a total of 2594 patients with multiple myeloma. All-grade and grades 3 and higher CVAE were seen in 617 (18.1%) and 274 (8.2%), respectively. Phase 2 or 3 studies and carfilzomib doses of 45 mg/m2 or higher were associated with high-grade CVAE. Median age older than 65 years, prior myeloma therapies, and concurrent myeloma therapies were not associated with CVAE. For the 3 randomized clinical trials, the summary relative risk of all-grade and grade 3 or higher CVAE for patients receiving carfilzomib compared with non-carfilzomib-receiving control patients were 1.8 and 2.2, respectively.
Conclusions and Relevance Carfilzomib was associated with a significant incidence of CVAE, with higher rates seen with higher doses of carfilzomib. Phase 1 studies may be under-detecting CVAE. Future studies are needed to identify patients at high risk for CVAE, develop optimal monitoring strategies, and explore strategies to mitigate these risks.”